Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.

U Jehn, V Heinemann
{"title":"Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.","authors":"U Jehn,&nbsp;V Heinemann","doi":"10.1007/978-3-642-74643-7_63","DOIUrl":null,"url":null,"abstract":"<p><p>Thirty-four consecutive patients with either relapsed (n = 28) or primary refractory AML (n = 6) were treated with one or two cycles of intermediate-dose (ID) cytosine arabinoside (Ara-C) (1 g/m2 i.v. q 12 h days 1-6) and amsacrine (m-AMSA) (120 mg/m2 i.v. days 5-7). Patients reaching complete remission (CR) were consolidated with one cycle of Ara-C 3 g/m2 i.v. q 12 h days 1-4 and m-AMSA 120 mg/m2 i.v. day 5. The median duration of the preceding remission was 8 months and median time from last chemotherapy until relapse 3.1 months. Of the relapsed patients, 22/28 (79%) achieved CR regardless of the type of prior intensive maintenance (HD Ara-C/m-AMSA/5-azacytidine) (AZA) or daunorubicin (DNR/CD-Ara-C). Three of the 28 (11%) patients died during hypoplasia; 3/28 (11%) were refractory to 2x ID-Ara-C/m-AMSA. Three of the 28 patients died in CR during hypoplasia after intensive consolidation with HD-Ara-C. Predictive factors for remission were duration of preceding remission and the time from last chemotherapy to relapse. Three patients were transplanted in second CR. One of the six refractory patients reached CR, two remained refractory, and three died during hypoplasia. The median duration of disease-free survival (DFS) of relapsed patients was 3.3 months without further treatment; median survival of responding patients (20 relapsed patients, 1 refractory patient) was 4.5 months, overall survival (n = 29) was 4.8 months. Patients receiving BMT were censored at the time of BMT. Seven patients experienced lung toxicity due to Ara-C, four of whom died.(ABSTRACT TRUNCATED AT 250 WORDS)</p>","PeriodicalId":12936,"journal":{"name":"Haematology and blood transfusion","volume":"33 ","pages":"333-8"},"PeriodicalIF":0.0000,"publicationDate":"1990-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Haematology and blood transfusion","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/978-3-642-74643-7_63","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

Thirty-four consecutive patients with either relapsed (n = 28) or primary refractory AML (n = 6) were treated with one or two cycles of intermediate-dose (ID) cytosine arabinoside (Ara-C) (1 g/m2 i.v. q 12 h days 1-6) and amsacrine (m-AMSA) (120 mg/m2 i.v. days 5-7). Patients reaching complete remission (CR) were consolidated with one cycle of Ara-C 3 g/m2 i.v. q 12 h days 1-4 and m-AMSA 120 mg/m2 i.v. day 5. The median duration of the preceding remission was 8 months and median time from last chemotherapy until relapse 3.1 months. Of the relapsed patients, 22/28 (79%) achieved CR regardless of the type of prior intensive maintenance (HD Ara-C/m-AMSA/5-azacytidine) (AZA) or daunorubicin (DNR/CD-Ara-C). Three of the 28 (11%) patients died during hypoplasia; 3/28 (11%) were refractory to 2x ID-Ara-C/m-AMSA. Three of the 28 patients died in CR during hypoplasia after intensive consolidation with HD-Ara-C. Predictive factors for remission were duration of preceding remission and the time from last chemotherapy to relapse. Three patients were transplanted in second CR. One of the six refractory patients reached CR, two remained refractory, and three died during hypoplasia. The median duration of disease-free survival (DFS) of relapsed patients was 3.3 months without further treatment; median survival of responding patients (20 relapsed patients, 1 refractory patient) was 4.5 months, overall survival (n = 29) was 4.8 months. Patients receiving BMT were censored at the time of BMT. Seven patients experienced lung toxicity due to Ara-C, four of whom died.(ABSTRACT TRUNCATED AT 250 WORDS)

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
中剂量Ara-C/m-AMSA用于缓解诱导,高剂量Ara-C/m-AMSA用于复发和难治性成人急性骨髓性白血病的强化巩固。
34例复发(n = 28)或原发性难治性AML患者(n = 6)连续接受1或2个周期的中剂量(ID)阿拉伯糖胞嘧啶(Ara-C) (1 g/m2静脉注射,第1-6天12小时)和amsacrine (m-AMSA) (120 mg/m2静脉注射,第5-7天)治疗。达到完全缓解(CR)的患者在第1-4天12小时内静脉注射Ara-C 3 g/m2,第5天静脉注射m-AMSA 120 mg/m2。前一次缓解的中位持续时间为8个月,从最后一次化疗到复发的中位时间为3.1个月。在复发患者中,22/28(79%)达到了CR,无论先前的强化维持(HD Ara-C/m-AMSA/5-阿扎胞苷)(AZA)或柔红霉素(DNR/CD-Ara-C)的类型如何。28例患者中有3例(11%)死于发育不全;3/28(11%)对2x ID-Ara-C/m-AMSA难治。经HD-Ara-C强化巩固后,28例患者中有3例死于发育不全期间的CR。缓解的预测因素是前一次缓解的持续时间和从最后一次化疗到复发的时间。3例患者在第二次CR中移植,6例难治性患者中1例达到CR, 2例仍难治性,3例因发育不全死亡。复发患者的中位无病生存期(DFS)为3.3个月,无需进一步治疗;缓解患者(20例复发患者,1例难治性患者)的中位生存期为4.5个月,总生存期(n = 29)为4.8个月。接受BMT的患者在BMT时被审查。7例患者因Ara-C出现肺毒性,其中4例死亡。(摘要删节250字)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Acute monocytic leukemia with translocation t(1;11) (p31;q23): simultaneous staining of chromosomes and cell surface antigens. Preliminary results of intensive therapy of children and adolescents with acute nonlymphocytic leukemia--a Childrens Cancer Study Group report. Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study. A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group. Pretherapeutic drug testing in acute leukemias for prediction of individual prognosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1